GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (MEX:SMMT) » Definitions » EV-to-FCF

Summit Therapeutics (MEX:SMMT) EV-to-FCF : -132.77 (As of Dec. 14, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Summit Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Summit Therapeutics's Enterprise Value is MXN270,050.90 Mil. Summit Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-2,033.97 Mil. Therefore, Summit Therapeutics's EV-to-FCF for today is -132.77.

The historical rank and industry rank for Summit Therapeutics's EV-to-FCF or its related term are showing as below:

MEX:SMMT' s EV-to-FCF Range Over the Past 10 Years
Min: -483.93   Med: -7.88   Max: 60.19
Current: -112.58

During the past 13 years, the highest EV-to-FCF of Summit Therapeutics was 60.19. The lowest was -483.93. And the median was -7.88.

MEX:SMMT's EV-to-FCF is ranked worse than
100% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs MEX:SMMT: -112.58

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Summit Therapeutics's stock price is MXN361.00. Summit Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN-4.384. Therefore, Summit Therapeutics's PE Ratio (TTM) for today is At Loss.


Summit Therapeutics EV-to-FCF Historical Data

The historical data trend for Summit Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics EV-to-FCF Chart

Summit Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -6.64 -2.67 -25.29 -22.78

Summit Therapeutics Quarterly Data
Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.22 -22.78 -30.47 -55.66 -138.81

Competitive Comparison of Summit Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Summit Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's EV-to-FCF falls into.



Summit Therapeutics EV-to-FCF Calculation

Summit Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=270050.904/-2033.967
=-132.77

Summit Therapeutics's current Enterprise Value is MXN270,050.90 Mil.
Summit Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-2,033.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Summit Therapeutics  (MEX:SMMT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Summit Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=361.00/-4.384
=At Loss

Summit Therapeutics's share price for today is MXN361.00.
Summit Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4.384.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Summit Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics Business Description

Traded in Other Exchanges
Address
601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.